ated with other erythroid transcription factors binding in the intergenic γ-δ sequences are also active in human globin switching in both fetal and adult-type hematopoietic progenitors and erythroid cells. Inhibition of the activity of these complexes -for example, by using siRNAs directed against Ikaros or other components of other complexes -is a potential approach to reactivating human γ-globin expression.
The data in the Chakalova et al. article also indicate an inverse relationship between γ-and β-globin accumulation in adult erythroid cells (7) . When there is more β-globin and HbA present, as found in the cells of patients doubly heterozygous for Corfu and β-thalassemia genes and patients heterozygous for the Corfu deletion, there are lower-than-expected levels of γ-globin and HbF accumulation (7) . These results suggest that in patients treated with butyrate or other HbF-inducing agents, downregulating human β-globin expression may be a useful approach to further optimize HbF production.
In summary, upregulation of γ-globin and/or downregulation of α-globin could reestablish normal globin balance between α-and non-α-globin chains and avoid the excess α-globin toxicity primarily responsible for anemia in human β-thalassemia. Achieving such a balance could ameliorate or even cure patients with these diseases. New insights into the mechanisms of globin regulation, such as those of Han et al. (3) , may eventually lead to new, more rational treatments for patients with β-thalassemia. Maintenance of health is critically dependent upon the immune system's ability to generate a balanced response to a variety of threats, real or perceived. Inflammatory responses of insufficient vigor can allow uncontrolled pathogen replication, events central to the development of malaria, TB, and HIV, the top infectious killers in the world today. On the other hand, excessive or inappropriate inflammatory responses place an equally heavy burden on humanity, being key to the pathogenesis of diverse infectious (e.g., sepsis, fulminant viral hepatitis), autoimmune (e.g., inflammatory bowel disease, multiple sclerosis), allergic (e.g., asthma), genetic (e.g., cystic fibrosis), and degenerative (e.g., atherosclerosis) diseases. It is thus not surprising that there has been considerable experimental, theoretical, and therapeutic interest in the molecular mechanisms that restrain the intensity of inflammatory responses. In addition to the usual suspects, such as cytokines, receptors, intracellular signaling inhibitors, and specialized suppressor cells, endogenous antiinflammatory lipid mediators have recently been recognized as playing an important role.
Counter-regulation by lipoxins and resolvins
Lipoxins are trihydroxytetraene-containing arachidonic acid metabolites that are produced by at least 3 distinct lipoxygenase (LO) pathways, involving interactions among diverse cell types, including leukocytes, epithelia, endothelia, and platelets ( Figure 1) (1, 4, 5) . This is a broad counter-regulatory profile, indeed. This profile, and the numerous reports of the beneficial effects of administering metabolically stable analogs in diverse mouse models of inflammatory pathology (1, 4, (6) (7) (8) (9) (10) , suggest that harnessing the pleiotropic activities of the lipoxins is a strategy with considerable therapeutic promise. Lipoxin therapy may be particularly apt for diseases such as severe asthma and cystic fibrosis, where lipoxin deficiency has been implicated in disease pathogenesis (11) (12) (13) . It should also be noted that, in addition to those generated from arachidonic acid, immunoregulatory mediators are also generated from omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid. Study of these latter mediators, named resolvins, is at an early stage, but immunologists (who have tended to pay little more than lip service to the biological importance of lipid mediators) should be aware that, like lipoxins, resolvins appear to have broad antiinflammatory, tissue protective, and catabatic properties (14, 15) .
Lipoxin-mediated control of the immune response to M. tuberculosis
In TB, bacterial persistence leads to a prolonged type 1 immune response in the lung that, while limiting bacterial growth, does not eliminate the highly inflammatory bacteria. This balance between bacte-
Figure 1
Lipoxin biosynthesis. There are at least 3 different biosynthetic pathways for lipoxin generation. All lead to the insertion of molecular oxygen at 2 sites in arachidonic acid by a variety of different enzymes that are generally segregated in different cell types and subject to regulation by cytokines and other inflammatory stimuli. In the first pathway (A), LXA4 is generated through the action of 15-LO from airway epithelia or myeloid cells (neutrophils, monocyte/macrophages), which is followed by the action of 5-LO in myeloid cells. In the second pathway (B), LXA4 is generated from leukotriene A4 (LTA4) (itself a product of 5-LO activity, and a leukotriene precursor) through the action of 15-LO or platelet-derived 12-LO. In the third pathway (C), arachidonic acid is converted to aspirin-triggered lipoxins (ATLs) such as 15-epi-LXA4, via the action of epithelial or endothelial COX-2 in the presence of aspirin, which is followed by the action of 5-LO. The ATLs have similar activities but greater functional potency due to their relative resistance to metabolic inactivation. These pathways likely operate both independently and in a coregulated fashion in different tissues and biological situations. H(p)ETE, hydroperoxyeicosatetraenoic acid; mono, monocyte/macrophage; PMN, polymorphonuclear neutrophil. ria and inflammation can be maintained for the life of the human host. However, breakdown leads to tissue damage, bacterial growth, and recrudescent disease. While the factors controlling this prolonged immune response have long been the subject of conjecture, the mechanisms responsible for counter-regulation during TB infection have remained obscure. The data implicating obvious candidates such as IL-10 and TGF-β, while intriguing, have remained associative in nature (16, 17) .
In this context, the current report by Bafica et al. (18) demonstrating that lipoxins are key modulators of the immune response to M. tuberculosis is of considerable interest. Murine infection with M. tuberculosis led to significant, 5-LO-dependent production of LXA 4 . In turn, infected, 5-LOknockout mice had increased expression of the type 1 mediators IL-12, IFN-γ, and NO synthase 2 (NOS2) (but not TNF), along with better control of mycobacterial replication and enhanced survival. Notably, systemic treatment of 5-LO knockouts with a metabolically stable LXA 4 analog reversed this enhanced control of mycobacterial replication. Such treatment also suppressed M. tuberculosis antigen-driven splenocyte production of IFN-γ (but, again, not TNF). These data provide clear evidence of biologically important, lipoxin-mediated counter-regulation in experimental TB infection and provide what is believed to be only the second example of host gene ablation leading to better control of experimental infection with this pernicious pathogen, the first being the demonstration of the apparent regulatory role of the IL-27 receptor (19) .
The lack of immunopathological consequences attending the upregulation of antimycobacterial immune responses in 5-LO-knockout mice is certainly a very welcome finding. This is not the case with T. gondii: despite improved control of parasite replication, 5-LO knockouts succumb rapidly to the encephalitic consequences of augmented inflammation during the early chronic phase of infection (5) . As discussed by Bafica et al. (18) , the different effect of 5-LO ablation on the course of these 2 infections likely relates to fundamental differences in the biology of the underlying pathogens. A vigorous Th1 response is necessary to contain infection with the rapidly replicating T. gondii, and such a response is induced in immunecompetent hosts. In contrast, the slowly replicating M. tuberculosis induces a less vigorous type 1 response (16) . Removal of lipoxin-mediated counter-regulation leads to better control of pathogen replication in both infections. But this advantage is lost in toxoplasmosis, when the unleashing of the more potent antitoxoplasma response leads to fatal immunopathology.
Taken together, the data presented by Bafica et al. (18) For those used to the relatively direct relationship between gene and mediator among immune-associated proteins, the complexities of lipid mediator generation can be somewhat daunting. Ablation of 5-LO would be expected to ablate both LXA 4 (and LXB 4 ) and leukotriene production -antiinflammatory and proinflammatory mediators alike. This was indeed found in the current study (18) . The overall effect of such ablation is, presumably, a reflection of the differing importance, kinetics, and cellular source of these mediators in the model in question. As for LXA 4 itself, although the enzymatic events required for its generation from arachidonic acid are clear (oxygenation at the C5 and C15 positions), the specific LO enzymes that are necessary in any given context remain to be determined. In addition to redundancy in activity (e.g., both 15-LO and 12-LO can insert oxygen at C15) and celltype specificity, there are 7 LO genes in the mouse genome. The potential for each of these enzymes to affect the availability and activity of lipid mediators needs to be addressed by careful biochemical study. And even these LOs do not exhaust the possible sources of LXA 4 generation during infection. Both T. gondii and P. aeruginosa encode enzymes with 15-LO activity (20, 21 
